Sageworth Trust Co Buys New Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Sageworth Trust Co purchased a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the 4th quarter, Holdings Channel.com reports. The firm purchased 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Other hedge funds also recently bought and sold shares of the company. Golden State Equity Partners grew its stake in shares of Sangamo Therapeutics by 2,592.3% in the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock worth $332,000 after buying an additional 313,587 shares in the last quarter. Shelton Wealth Management LLC purchased a new position in Sangamo Therapeutics in the fourth quarter worth about $29,000. Virtu Financial LLC bought a new stake in Sangamo Therapeutics during the third quarter worth approximately $150,000. Geode Capital Management LLC increased its stake in Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after acquiring an additional 272,123 shares during the last quarter. Finally, XTX Topco Ltd raised its position in Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Down 9.4 %

Shares of NASDAQ SGMO opened at $1.15 on Friday. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18. The business has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.37.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same period in the previous year, the company posted ($0.34) earnings per share. As a group, sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on SGMO. Truist Financial dropped their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Barclays boosted their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Wells Fargo & Company decreased their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Finally, StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.17.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.